Trial Profile
Efficacy of Brentuximab vedotin in patients with Hodgkin's lymphoma relapsed after autologous peripheral blood stem-cell transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Dec 2015
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 10 Dec 2015 New trial record